Search Results - "WASSERMAN, T. H"

American Society of Clinical Oncology Clinical practice guidelines for the use of chemotherapy and radiotherapy protectants by HENSLEY, M. L, SCHUCHTER, L. M, NEGRIN, R, SZATROWSKI, T. P, THIGPEN, J. T, VON HOFF, D, WASSERMAN, T. H, WINER, E. P, PFISTER, D. G, LINDLEY, C, MEROPOL, N. J, COHEN, G. I, BRODER, G, GRADISHAR, W. J, GREEN, D. M, LANGDON, R. J, MITCHELL, R. B

“…Because toxicities associated with chemotherapy and radiotherapy can adversely affect short- and long-term patient quality of life, can limit the dose and…”
Get full text

Outcome analysis for stage IE and IIE thyroid lymphoma by DiBiase, Steven J, Grigsby, Perry W, Guo, Chuanfa, Lin, H S, Wasserman, T H

“…Previous reports have revealed modest results in the management of thyroid lymphoma with radiotherapy alone. This retrospective report evaluates the outcome of…”
Get full text

Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin’s Disease by PRESS, Oliver W, LEBLANC, Michael, LICHTER, Allen S, GROGAN, Thomas M, UNGER, Joseph M, WASSERMAN, Todd H, GAYNOR, Ellen R, PETERSON, Bruce A, MILLER, Thomas P, FISHER, Richard I

“…The management of early-stage Hodgkin's disease in the United States is controversial. To evaluate whether staging laparotomy could be safely avoided in…”
Get full text

Plasmacytoma. Treatment results and conversion to myeloma by Holland, J, Trenkner, D A, Wasserman, T H, Fineberg, B

“…Forty-six cases of solitary plasmacytoma were reviewed for response to radiation and progression to multiple myeloma. Cases were classified as solitary…”
Get more information

Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison by Perez, C A, Michalski, J M, Purdy, J A, Wasserman, T H, Williams, K, Lockett, M A

“…We present preliminary results of a nonrandomized comparison of three-dimensional conformal radiation therapy (3D CRT) and standard radiation therapy (SRT) in…”
Get more information

Radiotherapeutic studies with amifostine (Ethyol) by Wasserman, T H

“…Radiotherapeutic studies with amifostine (WR-2721; Ethyol, US Bioscience, Inc, West Conshohocken, PA) are reviewed, with evidence that it offers clinical…”
Get more information

Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol by Russell, A H, Clyde, C, Wasserman, T H, Turner, S S, Rotman, M

“…This study was prepared to address two objectives: (a) to determine whether progressively higher total doses of hepatic irradiation can prolong survival in a…”
Get more information

The incidence of breast cancer following mantle field radiation therapy as a function of dose and technique by Tinger, A, Wasserman, T H, Klein, E E, Miller, E A, Roberts, T, Piephoff, J V, Kucik, N A

“…There is an increased incidence of breast cancer following mantle field radiation therapy for Hodgkin's disease (HD). We reviewed the experience at the…”
Get more information

Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer by BRIZEL, David M, WASSERMAN, Todd H, SAUER, Rolf, HENKE, Michael, STRNAD, Vratislav, RUDAT, Volkar, MONNIER, Alain, ESCHWEGE, Francois, ZHANG, Jay, RUSSELL, Lesley, OSTER, Wolfgang

“…Radiotherapy for head and neck cancer causes acute and chronic xerostomia and acute mucositis. Amifositine and its active metabolite, WR-1065, accumulate with…”
Get full text

Evaluation of the role of cellular hypoxia in sepsis by the hypoxic marker [18F]fluoromisonidazole by Hotchkiss, R S, Rust, R S, Dence, C S, Wasserman, T H, Song, S K, Hwang, D R, Karl, I E, Welch, M J

“…Underlying cellular hypoxia, which may be difficult to detect, has been postulated to be a major cause of morbidity and mortality in sepsis. We employed the…”
Get full text

A phase I-B trial of the radiosensitizer: Etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02) by Drzymala, R.E, Wasserman, T.H, Won, M, Shaw, E, Cmelak, A.J, Loeffler, J, Souhami, L

“…Abstract RTOG 95-02 assessed patient tolerance to hypoxic cell radiosensitizer, etanidazole (SR-2508), combined with radiosurgery. Patients had primary or…”
Get full text

Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28 by Epstein, B E, Scott, C B, Sause, W T, Rotman, M, Sneed, P K, Janjan, N A, Davis, L W, Selim, H, Mohiuddin, M, Wasserman, T H

“…Although there have been occasional reports of improved response with greater doses of irradiation for unresected brain metastases, dose escalation has not…”
Get more information

Cost benefit of emerging technology in localized carcinoma of the prostate by Perez, C A, Michalski, J, Ballard, S, Drzymala, R, Kobeissi, B J, Lockett, M A, Wasserman, T H

“…In a health care environment strongly concerned with cost containment, cost-benefit studies of new technology must include analyses of loco-regional tumor…”
Get more information

Radiation Therapy Oncology Group Quality of Life Assessment: Design, Analysis, and Data Management Issues by Scott, C. B., J. Stetz, Bruner, D. W., T. H. Wasserman

“…The Radiation Therapy Oncology Group (RTOG) has embarked on seven phase II or phase III multicentre clinical trials involving a quality of life component. Each…”
Get full text

Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features : A Phase II Cancer and Leukemia Group B study (9051) by WASSERMAN, T. H, PETRONI, G. R, MILLARD, F. E, CHUNG, C.-T, BARCOS, M, JOHNSON, J. L, CANELLOS, G. P, PETERSON, B. A

“…The aim of this study was to evaluate a regimen of sequential chemotherapy and radiotherapy for patients with Hodgkin disease. The Cancer and Leukemia Group B…”
Get full text

Cost accounting in radiation oncology: a computer-based model for reimbursement by Perez, C A, Kobeissi, B, Smith, B D, Fox, S, Grigsby, P W, Purdy, J A, Procter, H D, Wasserman, T H

“…The skyrocketing cost of medical care in the United States has resulted in multiple efforts in cost containment. The present work offers a rational…”
Get more information

Smoking and statistical overkill by Wasserman, H T

Get more information

Non-Hodgkin lymphoma: whole-abdomen irradiation as an adjuvant to chemotherapy by Valicenti, R K, Wasserman, T H, Monyak, D J, Kucik, N A

“…To evaluate the efficacy and toxicity of whole-abdomen irradiation in the treatment of abdominal non-Hodgkin lymphoma (NHL). Between 1978 and 1990, 39 patients…”
Get more information

Physician resource utilization in radiation oncology: a model based on management of carcinoma of the prostate by Kobeissi, B J, Gupta, M, Perez, C A, Dopuch, N, Michalski, J M, Van Antwerp, G, Gerber, R, Wasserman, T H

“…To develop a methodology to estimate the comparative cost of physician time in treating patients with localized prostate cancer, using as an example…”
Get more information

Non-Hodgkin's lymphoma of the stomach by Mittal, B, Wasserman, T H, Griffith, R C

“…Thirty-seven patients with non-Hodgkin's lymphoma of the stomach were treated with curative intent by several single and combined modality regimens. Twenty-two…”
Get more information